Results 41 to 50 of about 166,279 (314)

Nitric oxide plays a critical role in methotrexate-induced hyperplasia of enterochromaffin cells containing 5-hydroxytryptamine in rat small intestine

open access: yesJournal of Pharmacological Sciences, 2019
The role of nitric oxide (NO) in the changes in enterochromaffin cells and ileal 5-hydroxytryptamine (5-HT) content induced by a single i.p. administration of methotrexate was investigated in rats.
Yuho Takano   +11 more
doaj   +1 more source

The pharmacogenetics of methotrexate [PDF]

open access: yesRheumatology, 2007
Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately.
S L, Hider, I N, Bruce, W, Thomson
openaire   +2 more sources

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi   +5 more
wiley   +1 more source

Methotrexate Revisited—in Recurrent Head and Neck Cancer

open access: yes, 2011
Aims Response of single agent chemotherapy in improving quality of life in patients with recurrent head and neck cancers. Methods and material This is a study of the 18 patients with advanced cancers of head and neck, who had failed earlier attempts of ...
R.P.S. Banipal, M.K. Mahajan
core   +1 more source

Trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literature

open access: yes, 2020
Methotrexate is a cytotoxic agent that is commonly used to treat autoimmune diseases, and both solid and hematological malignancies. Drug interactions are of particular concern during methotrexate therapy, as they have the potential to alter the ...
King, LD, Anoopkumar-Dukie, S, Sia, H
core   +1 more source

Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study

open access: yesTherapeutic Advances in Drug Safety
Background: Methotrexate is central to the management of rheumatoid arthritis (RA). However, its use is often limited by methotrexate intolerance. Objectives: This study aims to explore the association between alternative methotrexate dosing methods and ...
Haya M. Almalag   +9 more
doaj   +1 more source

Histopathological effects of Methotrexate in mice livers [PDF]

open access: yesKirkuk Journal of Science, 2014
Background:Methotrexate is a folic acid antagonists that inhibits dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synthesis. Methotrexate has been used for the treatment of malignancy, rheumatic disorders,
Asal A. Tawfeeq Sundus M. Taifoor
doaj   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro   +6 more
wiley   +1 more source

Methotrexate Induces Apoptosis through P53/P21-Dependent Pathway and Increases E-Cadherin Expression through Downregulation of Hdac/Ezh2

open access: yes, 2012
Methotrexate MTX is a dihydrofolate reductase DHFR inhibitor widely used as an anticancer drug in different kinds of human cancers. Here we investigated the anti-tumor mechanism of MTX against non-small cell lung cancer NSCLC A549 cells.
HUANG, WEN-YU;YANG, PEI-MING;CHANG, YU-FAN;CHEN, CHING-CHOW   +1 more
core   +1 more source

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy